Biosearch Life has signed a license and exclusive distribution agreement with Angelini Farmacéutica, S.A. for the commercialization on the Spanish market of Hereditum® Lc40 oriented towards preventive and curative treatment of mastitis in lactating women.
• It is a preventive and curative treatment of mastitis – inflammation of the chest associated with breastfeeding- a disease which is the first medical cause of early abandonment of breastfeeding, a practice recommended by the WHO.
• Hereditum® strains, the only probiotic strains isolated from human breast milk, have been selected from among hundreds of different strains for their excellent properties and scientifically proven beneficial effects.
Madrid, April 25th, 2012
Biosearch Life, a biotechnology company of reference in the world of healthy ingredients, has announced the signing of a license and exclusive distribution agreement with Angelini Farmacéutica for the commercialization on the Spanish market of Hereditum® Lactobacillus Fermentum Lc40 oriented towards preventive and curative treatment of mastitis in breastfeeding women.
“We are very pleased by the signing of this agreement with Angelini Farmacéutica and we are confident that the outcome of this collaboration will be an invaluable support for breastfeeding mothers and the health of their infants.” “Over the years we have worked very hard on this project, so it fills us with pride to move it to the market and offer another innovative solution designed to improve our health and thus, our lives”, says Jose Mª Roset, Managing Director of Biosearch Life. “The collaboration with Angelini helps us continue to strengthen our position in the market.” “This agreement represents a step further in our commitment to develop innovative ingredients destined in the area of healthcare.”
Hereditum® is the brand associated with the range of Biosearch Life probiotic strains isolated and obtained from breast milk and are protected by various patents worldwide.
Besides its unique origin, as the rest of strains available on the market do not originate from human milk, Hereditum® strains have been selected from among hundreds of different strains for their excellent properties and scientifically proven beneficial effects.
The unique origin of Hereditum® makes these products not only excellent candidates for use in child nutrition, but their extraordinary properties and technological versatility ensures high performance and functionality in numerous applications for the pharmaceutical and functional food markets.
Mastitis is an inflammation of the chest associated with breastfeeding which is the first medical cause of the early abandonment of this practice (The World Health Organization recommends breastfeeding for at least the first six months of life of the newborn, for its benefits on health in the short and long term).
Up to fifteen per cent of women who choose to breastfeed their babies suffer from mastitis, a disease that appears during breastfeeding and that produces inflammation of the breast, in most cases accompanied by infection and severe pain. The treatment that is normally followed, antibiotics, works only in a reduced percentage of the treated cases and automatically implies the abandonment of breastfeeding.
Hereditum® Lactobacillus Fermentum Lc40 not only eliminates the painful symptoms associated with mastitis, it also ensures a low level of recurrence and, due to its natural origin, allows the mother to continue breastfeeding her newborn, with all the health benefits this entails for both of them.
Angelini Group produces and sells products for health and well-being. The activity of Angelini Group is based on research, development and marketing of products that meet the needs of the market, promoting constant supply of new opportunities for the pharmaceutical sector and human well-being.
Angelini offers a broad selection of products covering many different areas in the treatment and prevention fields.
After almost a century of dedication to the pharmaceutical industry, Angelini is currently present in more than 50 countries, where it holds a privileged position in different therapeutic areas: ophthalmology, central nervous system, locomotive apparatus, gynaecology, fertility, and paediatrics. It also participates in the OTC market.
Angelini Group has been present in Spain since 1978 through its division of Angelini Farmacéutica S.A.
Biosearch Life is a leader in biotechnology with innovative vocation at a global level. The company is present in the national and international markets supplying to the pharmaceutical, nutraceutical and functional food sectors, where it is present with its wide range of high quality services and products that revolve around the concept of a healthy life.
Biosearch Life designs bioactive ingredients allowing to develop drugs, dietary supplements and functional foods affecting, among others, the improvement of cardiovascular health, weight control, joint health, cognitive development, immune system or cellular aging.
Biosearch Life provides complete solutions to clients in more than 30 countries for those looking for maximum satisfaction with solutions and a solid portfolio of more than 200 products grouped in lipids, probiotic strains and natural extracts. The company is an international reference in the production and marketing of functional fatty acids (Omega 3), has a probiotic portfolio on the market which is unique for the origin from breast milk, and offers a full range of plant extracts. In addition, since its creation, Biosearch Life has developed numerous patents worldwide which are the outcome of its efforts in research and development.
Biosearch Life sells its products under three brand names: Eupoly® for its products based on omega 3; Hereditum® for its range of probiotic strains; and Exxentia® for the vegetable extract line.
For more information:
Biosearch life –Comunication Dpt.
Tfno. +34 91 380 29 73
Tfno. +34 91 788 32 00